
Tech entrepreneur Bryan Johnson, who spends $2 million annually on anti-aging treatments, refutes claims that Novo Nordisk AS‘s (NYSE:NVO) Ozempic demonstrates anti-aging properties. Johnson disputed a post on social platform X suggesting the diabetes drug reverses biological aging by 3.1 years.